Comparative Efficacy and Safety of Obicetrapib vs Bempedoic Acid on top of Statin Therapy: A Network Meta-Analysis

Key Points

• Obicetrapib shows superior efficacy in reducing LDL cholesterol compared with bempedoic acid, supporting its use in patients on statins.
• The analysis identifies a statistically significant difference, with LDL cholesterol reduction of 30 mg/dL for obicetrapib.
• Network meta-analysis of multiple trials assessed both interventions, indicating a robust comparison across therapies.
• Findings may guide clinicians in optimizing cholesterol-lowering strategies with safety considerations of both drugs.